Pfizer Initiates Class II Recall of Buprenorphine Hydrochloride Injection Due to Sterility Concerns
Pfizer Inc. has initiated a Class II recall for 84,710 cartridges of Buprenorphine Hydrochloride Injection across the U.S. and Puerto Rico. This voluntary action, prompted by potential incomplete crimp seals and sterility assurance risks, demands immediate attention from procurement and regulatory teams. The event underscores critical supply chain vulnerabilities for essential medications and necessitates robust quality control assessments.
FDA Findings: Pfizer's Buprenorphine Hydrochloride Injection Recall Due to Sterility Risk
Pfizer Inc. has initiated a voluntary Class II recall, identified as D-0564-2024, for specific lots of Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit. This critical action, initiated on May 20, 2024, stems from a lack of assurance of sterility, specifically citing the potential for incomplete crimp seals on the product packaging. For procurement directors and supply chain VPs, this means an immediate need to verify the integrity of any Buprenorphine Hydrochloride stock originating from Pfizer, distributed by Hospira, Inc., Lake Forest, IL 60045 USA. The recall affects a substantial quantity of 84,710 cartridges, covering lot numbers HJ3965 (expiration September 2024) and HJ8546 (expiration October 2024). The widespread distribution pattern, encompassing US Nationwide and Puerto Rico, indicates a significant market exposure for this essential medication. Regulatory affairs heads must recognize that a Class II classification signifies a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates swift internal review and communication regarding the affected product to mitigate patient risk and ensure compliance.
Commercial Impact and Supply Chain Vulnerabilities for Buprenorphine Hydrochloride
The recall of Buprenorphine Hydrochloride Injection by Pfizer Inc. carries significant commercial ramifications beyond immediate product retrieval. Buprenorphine Hydrochloride (ANDA074137) is a critical human prescription drug, administered via intramuscular or intravenous routes, primarily used in pain management and the treatment of opioid dependence. The withdrawal of 84,710 cartridges from the US and Puerto Rico markets represents a tangible reduction in available supply, potentially impacting healthcare providers and patients reliant on this specific formulation. For business development executives, this event highlights the fragility of single-source or limited-source supply chains for essential medicines. While Hospira, Inc. is listed as the manufacturer, Pfizer Inc. bears the responsibility as the recalling firm, impacting its brand reputation and potentially leading to lost sales and increased operational costs associated with managing the recall process. Procurement directors must assess their current inventory against the affected lots (HJ3965, HJ8546) and immediately explore alternative sourcing strategies for Buprenorphine Hydrochloride to prevent potential stockouts and ensure continuity of patient care, even as the market adjusts to this disruption.
Navigating Sterility Assurance Risks in Pharmaceutical Supply Chains
This Class II recall of Buprenorphine Hydrochloride Injection due to incomplete crimp seals underscores a recurring and critical challenge within the pharmaceutical industry: maintaining absolute sterility assurance for injectable products. The potential for compromised container closure integrity directly jeopardizes patient safety by allowing microbial ingress. This incident is not isolated; a parallel event, the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection in June 2026, also cited failures in sterility assurance. Such repeated occurrences signal to regulatory affairs heads that the FDA is intensifying its scrutiny on manufacturing processes related to sterile product packaging. For procurement teams, this necessitates a more rigorous approach to supplier qualification, extending beyond API quality to encompass the entire finished product manufacturing and packaging process. Specific attention must be paid to container closure systems, including crimp seal integrity, and robust quality control measures must be in place to detect potential defects before products reach the market. Proactive risk assessments of all sterile injectable products in your portfolio are now more imperative than ever to prevent similar costly and reputation-damaging recalls.
Strategic Considerations for Procurement and Regulatory Teams Post-Recall
In the wake of Pfizer Inc.'s Buprenorphine Hydrochloride Injection recall, senior decision-makers must implement strategic adjustments to mitigate future risks. For procurement directors, this event reinforces the imperative of supply chain diversification, particularly for critical care medications. While specific alternative suppliers for this exact formulation are not detailed in the available intelligence, the principle of not relying on a single manufacturing pathway is paramount. Enhanced supplier audits should now explicitly include detailed reviews of container closure integrity testing protocols and validation data for sterile products. Regulatory affairs heads should leverage this incident to re-evaluate their internal quality management systems, focusing on cGMP compliance related to aseptic processing and packaging. This includes reviewing batch records, environmental monitoring data, and personnel training for operations involving sterile product handling. Business development executives should monitor the market for opportunities that may arise from this supply disruption, potentially through partnerships or investments in manufacturers with robust sterility assurance track records. The ongoing status of this recall means continuous monitoring of Pfizer's remediation efforts and any subsequent FDA communications will be crucial for informed decision-making.